1、单克隆抗体的开发、筛选与工程化改造
2、双特异性抗体的设计与研究
3、新型抗体偶联药物（ADCs）的设计与评价
4、抗体抗肿瘤免疫机制与自身免疫性疾病机制研究
1、单克隆抗体的开发、筛选与工程化改造
2、双特异性抗体的设计与研究
3、新型抗体偶联药物（ADCs）的设计与评价
4、抗体抗肿瘤免疫机制与自身免疫性疾病机制研究
1. 靶向人CD24单抗与一氧化氮供体偶联物的设计及其抗肝癌机制的研究（国家自然科学基金，2020.1-2023.12）
2. 干扰素突变体融合抗体的分子设计及其激活肿瘤微环境免疫活性的机制研究（江苏省自然科学基金，2016.7-2019.6）
3. 基于VEGFR2 单抗的融合抗体分子设计及其激活NKG2D 途径免疫监视作用的研究（国家自然科学基金，2014.1-2017.12）
4. 靶向肿瘤干细胞人源DLL4 抗体抗肿瘤活性及机制研究（国家自然科学基金， 2013.1-2016.12）
5. 新型双特异性抗EGFR/KDR 人源抗体的构建及其抗肿瘤作用的研究（国家自然科学基金，编号81102364，2012.1-2014.12）
6.抗体药物开发等相关校企横向合作项目多项
1. Yang P, Yu F, Yao Z, Ding X, Xu H*, Zhang J*. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer. Cancer Immunol Immunother. 2023 Oct;72(10):3191-3202.
2. Pan M, Wang F, Nan L, Yang S, Qi J, Xie J, Shao S, Zou H, Wang M, Sun F, Zhang J*. αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade. Cancer Immunol Immunother. 2023 Apr;72(4):969-984.
3. You J, Zhang J*, Wang J, Jin M. Cysteine-Based Coupling: Challenges and Solutions. Bioconjug Chem. 2021 Aug 18;32(8):1525-1534.
4. Shang P, Gao R, Zhu Y, Zhang X, Wang Y, Guo M, Peng H, Wang M, Zhang J*. VEGFR2-targeted antibody fused with IFN α mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity. Acta Pharm Sin B. 2021 Feb;11(2):420-433.
5. Wang Y, Li H, Xu W, Pan M, Qiao C, Cai J, Xu J, Wang M*, Zhang J*. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma. J Immunother. 2020 Jul/Aug;43(6):175-188.
6. Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J*. Antibody-Drug Conjugates: A Comprehensive Review. Mol Cancer Res. 2020 Jan;18(1):3-19.
7. Sun F, Wang Y, Luo X, Ma Z, Xu Y, Zhang X, Lv T, Zhang Y, Wang M, Huang Z*, Zhang J*. Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. Cancer Res. 2019 Jul 1;79(13):3395-3405.
8.Xu Y, Zhang X, Wang Y, Pan M, Wang M*, Zhang J*. A VEGFR2-MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice. Cancer Immunol Immunother. 2019 Sep;68(9):1429-1441.
1. Yang P, Yu F, Yao Z, Ding X, Xu H*, Zhang J*. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer. Cancer Immunol Immunother. 2023 Oct;72(10):3191-3202.
2. Pan M, Wang F, Nan L, Yang S, Qi J, Xie J, Shao S, Zou H, Wang M, Sun F, Zhang J*. αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade. Cancer Immunol Immunother. 2023 Apr;72(4):969-984.
3. You J, Zhang J*, Wang J, Jin M. Cysteine-Based Coupling: Challenges and Solutions. Bioconjug Chem. 2021 Aug 18;32(8):1525-1534.
4. Shang P, Gao R, Zhu Y, Zhang X, Wang Y, Guo M, Peng H, Wang M, Zhang J*. VEGFR2-targeted antibody fused with IFN α mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity. Acta Pharm Sin B. 2021 Feb;11(2):420-433.
5. Wang Y, Li H, Xu W, Pan M, Qiao C, Cai J, Xu J, Wang M*, Zhang J*. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma. J Immunother. 2020 Jul/Aug;43(6):175-188.
6. Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J*. Antibody-Drug Conjugates: A Comprehensive Review. Mol Cancer Res. 2020 Jan;18(1):3-19.
7. Sun F, Wang Y, Luo X, Ma Z, Xu Y, Zhang X, Lv T, Zhang Y, Wang M, Huang Z*, Zhang J*. Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. Cancer Res. 2019 Jul 1;79(13):3395-3405.
8.Xu Y, Zhang X, Wang Y, Pan M, Wang M*, Zhang J*. A VEGFR2-MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice. Cancer Immunol Immunother. 2019 Sep;68(9):1429-1441.
